$FTH News
Last published 13h ago
- 13h agoFTHFaeth Therapeutics to Participate in Upcoming November Investor ConferencesBusiness WireAUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced that management will participate in the following upcoming investor conferences: Guggenheim 3rd Annual Healthcare Innovation Conference Wednesday, November 11, 2026 1x1 investor meetings Boston, M ...
- 2d agoFTHFaeth Reports Positive Preliminary Phase 2 Topline Results from the PIK-201 Trial Evaluating PIKTOR in Combination with Paclitaxel in Patients with Advanced Endometrial CancerBusiness WireAUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced topline clinical data from its Phase 2 trial (FTH-PIK-201; NCT06463028; GOG-3111) of PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib, given with paclitaxel to patie ...
- 5d agoFTHFaeth to Report PIK-201 Phase 2 Data and Host Virtual Event on November 9, 2026Business WireAUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical- stage biotechnology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced that it will host a virtual event on Monday, November 9 at 8:00 AM ET to discuss topline results from its Phase 2 PIK-201 trial exploring PIKTOR in advanced endometrial cancer. To register, ...
- 1w agoFTHFaeth Therapeutics, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 2w agoFTHZYMEFaeth Appoints Adam Schayowitz, Ph.D., MBA, Head of Research and Development at Zymeworks, to Board of DirectorsBusiness WireDr. Schayowitz brings nearly 20 years of oncology drug development experience, including development leadership roles at Pfizer Oncology and Tesaro Dr. Schayowitz has led dozens of global development programs and led
- 2w agoFTHFaeth Presents Updated Preclinical Data at ESMO, including First-Ever Head-to-Head Characterization of PIKTOR against GedatolisibBusiness WireIn two preclinical breast cancer xenograft models (abstract #431P), PIKTOR inhibited tumor growth to a comparable or greater extent than intravenous gedatolisibPIKTOR inhibited HR+/HER2- breast cancer xenograft tumor
- 2w agoFTHFaeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireFaeth Therapeutics, Inc. (NASDAQ:FTH) today announced that the Compensation Committee of Faeth’s Board of Directors granted three new employees options to purchase an aggregate of 17,000 shares of the Company’s common
- 3w agoFTHFaeth to Present Preclinical Data on PIKTOR in HR+/HER2- Breast Cancer Models at ESMO 2026Business WirePoster will characterize the efficacy of PIKTOR as a monotherapy and in combination with fulvestrant, oral SERDs, and CDK inhibitors in preclinical models of breast cancerPoster also includes results from head-to-head
- 1mo agoFTHFaeth Therapeutics Appoints Karen Vousden, Ph.D., to Board of DirectorsBusiness WireRenowned cancer biologist and Faeth scientific co-founder joins the Board as the Company approaches topline Phase 2 data for PIKTOR in endometrial cancerFaeth Therapeutics, Inc. (NASDAQ:FTH), a clinical-stage
- 1mo agoSNSEFTHFaeth Therapeutics - 1773851 - FAETH THERAPEUTICS INCEarnings Call TranscriptsOkay, good morning. Thank you everyone for joining here for the third day of the Morgan Stanley Healthcare Conference. My name is Jason Russell, I'm the Managing Director with the team, and it is a pleasure to be joined
- 2mo agoFTHFaeth Therapeutics to Host Virtual KOL Event on Multi-Nodal Inhibition for the Treatment of Endometrial Cancer on October 6, 2026Business WireFaeth Therapeutics (NASDAQ:FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced that it will host a virtual key opinion leader
- 2mo agoFTHFaeth Therapeutics to Participate in Upcoming September Investor ConferencesBusiness WireFaeth Therapeutics (NASDAQ:FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced that management will participate in the
- 2mo agoFTHFaeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireFaeth Therapeutics, Inc. (NASDAQ:FTH) today announced that the Compensation Committee of Faeth’s Board of Directors granted three new employees options to purchase an aggregate of 94,000 shares of the Company’s common
- 2mo agoFTHFaeth Therapeutics Announces FDA Grant of Fast Track Designation for PIKTOR Plus Paclitaxel in Biomarker-Selected Advanced Endometrial CancerBusiness Wire— Fast Track designation applies to sapanisertib and serabelisib (PIKTOR) in combination with paclitaxel for the treatment of patients with advanced or recurrent endometrial cancer whose tumors harbor a PI3K/AKT/mTOR
- 2mo agoFTHFaeth Therapeutics Strengthens Executive Team with Senior Leadership AppointmentsBusiness WireAppointments reinforce technical operations and investor engagement as the company advances its clinical programs Faeth Therapeutics, Inc. (NASDAQ:FTH) today announced the appointments of Deepak Tiwari as Senior Vice
- 3mo agoFTHFaeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireFaeth Therapeutics, Inc. (NASDAQ:FTH) today announced that the Compensation Committee of Faeth’s Board of Directors granted two new employees options to purchase an aggregate of 11,000 shares of the Company’s common
- 3mo agoFTHFaeth Therapeutics to Present PK/PD Modeling That Informed PIKTOR Dose Selection in Ongoing FTH-PIK-201 Trial at Upcoming Scientific ConferenceBusiness Wire— The data will be presented at the 2026 Summit for Novel Therapeutics in Oncology and Precision Medicine in Cancer conference on August 8 — These data collectively informed PIKTOR dose selection in the ongoing Phase
- 3mo agoFTHFaeth Therapeutics Reports Second Quarter 2026 Financial Results and Operational UpdatesBusiness Wire— Topline results from the Phase 2 PIK-201 trial in endometrial cancer on track for year-end — First patient dosed in the Phase 1b/2 PIK-101 trial in HR+ breast cancer — Company changed name to Faeth Therapeutics,
- 3mo agoFTHFaeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireFaeth Therapeutics, Inc. (NASDAQ:FTH) today announced that the Compensation Committee of Faeth’s Board of Directors granted two new employees options to purchase an aggregate of 25,500 shares of the Company’s common
- 4mo agoFTHFaeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireFaeth Therapeutics, Inc. (NASDAQ:FTH) today announced that the Compensation Committee of Faeth’s Board of Directors granted six new employees options to purchase an aggregate of 180,350 shares of the Company’s common
- 4mo agoSNSEFTHSensei Biotherapeutics Announces Name Change to Faeth Therapeutics, Focused on Advancing PIKTOR, an Oral Therapy Targeting One of the Most Frequently Altered Pathways in CancerBusiness Wire— Stockholders approved conversion of the Series B preferred stock issued in the February 2026 acquisition of Faeth Therapeutics and concurrent private placement — — Company changed name to Faeth Therapeutics, Inc. on